Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating polycystic kidney disease and use thereof

A composition and medicine technology, applied in the field of pharmaceutical compositions and their applications and pharmaceutical preparations containing the same, can solve the problems of liver damage, increased incidence of heart failure, water and sodium retention and the like

Active Publication Date: 2009-04-01
CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although rosiglitazone and pioglitazone are more active than troglitazone and have less liver toxicity, long-term use still has adverse reactions such as liver damage, water and sodium retention, weight gain, and increased incidence of heart failure [Journal of Adverse Drug Reactions, 2004 No. 2, p. 137; No. 6, 2002, p. 418]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating polycystic kidney disease and use thereof
  • Medicine composition for treating polycystic kidney disease and use thereof
  • Medicine composition for treating polycystic kidney disease and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] To observe the renal protective effects and side effects of long-term application of rosiglitazone, amiloride and their combination on ADPKD animal model Han: SPRD rats.

[0044] Experimental materials and methods

[0045] ADPKD animal model Han: SPRD rats were imported from the Mayo Clinic Medical Center in the United States and have been bred stably in the Experimental Animal Center of the Second Military Medical University for nearly 7 years. The inventor took Han:SPRD male 3-week-old heterozygous cy / + rats as intervention objects, and set up negative control group, rosiglitazone group (0.56mg / kg.d), amiloride group (0.35mg / kg .d) and 5 combined medication groups: amiloride+rosiglitazone (0.35mg / kg.d+0.56mg / kg.d), amiloride+rosiglitazone (0.175mg / kg.d +0.56mg / kg.d), amiloride+rosiglitazone (0.35mg / kg.d+1.12mg / kg.d), amiloride+rosiglitazone (0.35mg / kg.d +0.28mg / kg.d), amiloride+rosiglitazone (0.70mg / kg.d+0.56mg / kg.d). Gastrointestinal administration for 5 months, o...

Embodiment 2

[0064] Embodiment 2: Compound (amiloride hydrochloride+rosiglitazone maleate) solution

[0065] Prescription: Amiloride Hydrochloride 2.5g

[0066] Rosiglitazone Maleate 5g

[0067] Sodium Lauryl Sulfate 0.1g

[0068] Distilled water appropriate amount 10000ml

[0069] Process: Take the above-mentioned amiloride hydrochloride, rosiglitazone maleate and sodium lauryl sulfate, add 1000ml of distilled water to dissolve, then add 10000ml of distilled water to obtain.

Embodiment 3

[0070] Embodiment 3: Compound (amiloride hydrochloride + rosiglitazone maleate) syrup

[0071] Prescription: Amiloride Hydrochloride 1g

[0072] Rosiglitazone Maleate 2g

[0073] Distilled water 1500ml

[0074]Add simple syrup to 10000ml

[0075] Process: Dissolve amiloride hydrochloride and rosiglitazone maleate in distilled water, add simple syrup to the full amount, and obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating polycystic kidney disease. The active ingredients of the pharmaceutical composition comprise effective doses of thiazolidinediones and diuretics. The preferential combination is as follows: the thiazolidinediones are selected from rosiglitazone and the diuretics are selected from amiloride hydrochloride. The animal experiments prove that the efficacy of the composition of the rosiglitazone and the diuretics on the treatment of the polycystic kidney disease is better than the single use of one drug. The effect of the pharmaceutical composition for treating the polycystic kidney disease is better than the single use of one drug, thereby being a drug for treating the polycystic kidney disease and being worth expecting.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition for treating polycystic kidney disease, an application thereof and a pharmaceutical preparation containing the same. Background technique [0002] According to the mode of inheritance, polycystic kidney disease is divided into autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (autosomal recessive polycystic kidney disease, ARPKD). Among them, ADPKD is one of the most common and most harmful monogenic genetic diseases in humans, ranking first in hereditary kidney diseases. The incidence rate of ADPKD in the world is 1 / 400-1 / 1000. At present, there are more than 1.5 million people suffering from this disease in my country, and 50% of them will progress to end-stage renal failure at the age of 60. It is characterized by multiple fluid cysts of different sizes in the cortex and medulla of the bilateral kidneys...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K9/00A61K9/02A61K9/06A61K9/08A61K9/10A61K9/107A61K9/14A61K9/16A61K9/20A61K9/22A61K9/48A61K9/70A61K31/4965A61P13/12A61K31/4436
Inventor 梅长林顾书华樊榕
Owner CHANGZHOU HI TECH DISTRICT MULTIPLE DIMENSION IND TECH INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com